EML4 and cancer: Revealing coexistence of double ALK fusion: EML4-ALK (E6:A20, MAF = 24.7%) and ALK-SSH2 (A19:S3, MAF = 0.85%) (Fig. 2B), which was further validated by another NGS 10 cancer‐related gene panel (RNA-based detection for fusion genes, Amoy Diagnostics, Xiamen, China), EML4-ALK ALK-SSH2 (E6:A20, MAF = 25.6%; A19:S3, MAF = 0.68%, respectively) (Fig. 2 C).